Skip to Content
Merck
CN

224235

N,N′-Hexamethylene bis(acetamide)

98%

Synonym(s):

N,N′-Diacetyl-1,6-hexanediamine, HMBA

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Linear Formula:
CH3CONH(CH2)6NHCOCH3
CAS Number:
Molecular Weight:
200.28
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
98%
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

N,N′-Hexamethylene bis(acetamide), 98%

InChI

1S/C10H20N2O2/c1-9(13)11-7-5-3-4-6-8-12-10(2)14/h3-8H2,1-2H3,(H,11,13)(H,12,14)

SMILES string

CC(=O)NCCCCCCNC(C)=O

InChI key

BNQSTAOJRULKNX-UHFFFAOYSA-N

assay

98%

mp

128-129 °C (lit.)

solubility

water: soluble 5%, clear, colorless

functional group

amide

Looking for similar products? Visit Product Comparison Guide

Application

N,N′-Hexamethylene bis(acetamide) was used as an inducing agent in obtaining mononuclear cells from the peripheral blood (PB) sample by Ficoll-Hypaque gradient separation.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xuguang Zhu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(2), 430-440 (2016-07-22)
New therapeutic approaches are needed for patients with thyroid cancer refractory to radioiodine treatment. An inhibitor of bromodomain and extraterminal domain (BET) proteins, JQ1, shows potent antitumor effects in hematological cancers and solid tumors. To evaluate whether JQ1 is effective
Wali Hafezi et al.
PLoS pathogens, 8(5), e1002679-e1002679 (2012-05-17)
Following productive, lytic infection in epithelia, herpes simplex virus type 1 (HSV-1) establishes a lifelong latent infection in sensory neurons that is interrupted by episodes of reactivation. In order to better understand what triggers this lytic/latent decision in neurons, we
Shailesh K Choudhary et al.
The Journal of infectious diseases, 197(8), 1162-1170 (2008-04-19)
Novel therapeutic approaches are needed to attack persistent proviral human immunodeficiency type 1 (HIV-1) infection. Hexamethylbisacetamide (HMBA), a hybrid bipolar compound, induces expression of the HIV-1 promoter in the long terminal repeat (LTR) region in a Tat-independent manner but mimics
Richard L Thompson et al.
PLoS pathogens, 5(3), e1000352-e1000352 (2009-03-28)
The mechanism controlling the exit from herpes simplex virus latency (HSV) is of central importance to recurrent disease and transmission of infection, yet interactions between host and viral functions that govern this process remain unclear. The cascade of HSV gene
Samuel T Workenhe et al.
Communications biology, 3(1), 645-645 (2020-11-06)
Cancer immunotherapies using monoclonal antibodies to block inhibitory checkpoints are showing durable remissions in many types of cancer patients, although the majority of breast cancer patients acquire little benefit. Human melanoma and lung cancer patient studies suggest that immune checkpoint

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service